Weight Regain Has a Glucose Signature: What a CGM Shows if You Stop
“The diabetic who knows the most, lives the longest.”
The weight-regain story after stopping a GLP-1 is well documented. The glucose side of that story is less talked about, and it's the part a CGM makes visible. If the drug's benefit fades when you stop, your sensor is where you'd see it happen first.
What the trials show about stopping
The discontinuation evidence is consistent. In STEP 4, people who stopped semaglutide regained much of the weight they had lost, while those who kept going kept losing (Rubino 2021). SURMOUNT-4 showed the same shape for tirzepatide, with substantial regain after stopping (Aronne 2024). The STEP 1 extension found participants regained roughly two-thirds of their lost weight within about a year of coming off the drug and its support (Wilding 2022). The pattern is the same across all three: the benefit is on-treatment, and it reverses when treatment stops.
Why glucose follows the weight
The mechanisms that flatten your glucose on a GLP-1, slowed digestion, glucose-timed insulin, suppressed glucagon, only operate while the drug is in your system. Remove it, and those effects wind down. As appetite returns and meals get bigger and faster again, the post-meal spikes the drug had been smoothing tend to come back. So the glucose curve often loosens on a similar timeline to the weight returning. Watched on a CGM, that looks like taller peaks and a rising variability trend rather than a single dramatic event.
Why this is honest, not discouraging
It would be easy to hide the come-off data. Showing it is the more trustworthy move, because it lines up the value of monitoring with how the drug actually works. A CGM documents the benefit while you're on the drug and documents it fading if you stop. That's not a scare tactic. It's the same truth behind any chronic-condition medication, and seeing it on your own sensor turns an abstract warning into information you can plan around.
If you're thinking about stopping
Talk to your clinician first, and consider watching your glucose through the transition rather than flying blind. A sensor can show you how fast your patterns change, whether your peaks are climbing, and how your steadiness trends in the weeks after. That data makes the decision, and any plan to restart or adjust, a lot less of a guess.
Watch the whole arc, on and off
The benefit of a GLP-1 is easiest to understand when you can see it, both while it's working and if it fades. Endobits tracks your glucose patterns across the full arc of therapy, so a change in direction shows up early instead of by surprise. Start with Endobits →
Sources
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA, 2021. 10.1001/jama.2021.3224
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA, 2024. 10.1001/jama.2023.24945
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes, Obesity and Metabolism, 2022. 10.1111/dom.14725